Literature DB >> 20940706

Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector.

Naoya Uchida1, Kareem N Washington, Coen J Lap, Matthew M Hsieh, John F Tisdale.   

Abstract

Position effects limit the curative potential of gene transfer strategies for the hemoglobinopathies by inducing clonal variability of transgene expression. We evaluated the mitigating effects of the chicken hypersensitivity site 4 (HS4) insulator among lentiviral vector-transduced human hematopoietic cells. We constructed various lentiviral vectors using a green fluorescent protein (GFP) reporter under the control of a reverse-oriented murine stem cell virus (MSCV)-long-term repeat (LTR) promoter or a reverse-oriented β-globin expression cassette. A full-length HS4, a tandem HS4 core, and a single core insulator were inserted into the 3' LTR in both forward and reverse orientation. All but the reverse single core insulator significantly decreased titers. All reduced %GFP without increasing mean fluorescence intensity (MFI) among erythroid progeny of transduced human CD34(+) cells. A lower coefficient of variation (CV) was observed only among progeny of the full-length vector-transduced cells, yet a fivefold reduction in transduction efficiency was observed. In xenografted mice, the single core insulator decreased both the %GFP and the MFI at 4 and 8 weeks after transplantation with no difference in CVs. These data demonstrate that the inclusion of HS4 insulator elements lowers viral titers, reduces efficiency of transduction, and produces minimal effects on transgene expression among human hematopoietic cells in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940706      PMCID: PMC3017448          DOI: 10.1038/mt.2010.218

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  HIV-1 genome nuclear import is mediated by a central DNA flap.

Authors:  V Zennou; C Petit; D Guetard; U Nerhbass; L Montagnier; P Charneau
Journal:  Cell       Date:  2000-04-14       Impact factor: 41.582

2.  Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood.

Authors:  Hideki Hanawa; Patrick F Kelly; Amit C Nathwani; Derek A Persons; Jody A Vandergriff; Phillip Hargrove; Elio F Vanin; Arthur W Nienhuis
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

3.  Gene therapy continues to mature and to face challenges.

Authors:  David A Williams
Journal:  Mol Ther       Date:  2009-08       Impact factor: 11.454

4.  Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells.

Authors:  Ghiabe H Guibinga; Atsushi Miyanohara; Jeffrey D Esko; Theodore Friedmann
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

5.  Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.

Authors:  C May; S Rivella; J Callegari; G Heller; K M Gaensler; L Luzzatto; M Sadelain
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

6.  Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy.

Authors:  D A Persons; E R Allay; D E Sabatino; P Kelly; D M Bodine; A W Nienhuis
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

Review 7.  Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.

Authors:  Derek A Persons
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.

Authors:  Elizabeth M Kang; Uimook Choi; Narda Theobald; Gilda Linton; Debra A Long Priel; Doug Kuhns; Harry L Malech
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

9.  Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.

Authors:  Naoya Uchida; Hideki Hanawa; Kazuo Dan; Koiti Inokuchi; Takashi Shimada
Journal:  J Nippon Med Sch       Date:  2009-06       Impact factor: 0.920

10.  Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells.

Authors:  Naoya Uchida; Kareem N Washington; Jun Hayakawa; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more
  20 in total

1.  RNA Trans-Splicing Targeting Endogenous β-Globin Pre-Messenger RNA in Human Erythroid Cells.

Authors:  Naoya Uchida; Kareem N Washington; Brian Mozer; Charlotte Platner; Josiah Ballantine; Luke P Skala; Lydia Raines; Anna Shvygin; Matthew M Hsieh; Lloyd G Mitchell; John F Tisdale
Journal:  Hum Gene Ther Methods       Date:  2017-02-14       Impact factor: 2.396

2.  High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector.

Authors:  Naoya Uchida; Phillip W Hargrove; Coen J Lap; Molly E Evans; Oswald Phang; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Anh-Dao Nguyen; Matthew M Hsieh; Tyra G Wolfsberg; Robert E Donahue; Derek A Persons; John F Tisdale
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

3.  TRIM5α variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo.

Authors:  Molly E Evans; Chutima Kumkhaek; Matthew M Hsieh; Robert E Donahue; John F Tisdale; Naoya Uchida
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

4.  Evaluation of engraftment and immunological tolerance after reduced intensity conditioning in a rhesus hematopoietic stem cell gene therapy model.

Authors:  N Uchida; R P Weitzel; M E Evans; R Green; A C Bonifacino; A E Krouse; M E Metzger; M M Hsieh; R E Donahue; J F Tisdale
Journal:  Gene Ther       Date:  2013-11-21       Impact factor: 5.250

5.  Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.

Authors:  Naoya Uchida; Aylin Bonifacino; Allen E Krouse; Mark E Metzger; Gyorgy Csako; Agnes Lee-Stroka; Ross M Fasano; Susan F Leitman; Joseph J Mattapallil; Matthew M Hsieh; John F Tisdale; Robert E Donahue
Journal:  Exp Hematol       Date:  2011-04-15       Impact factor: 3.084

6.  Kinetics of lentiviral vector transduction in human CD34(+) cells.

Authors:  Naoya Uchida; Rashidah Green; Josiah Ballantine; Luke P Skala; Matthew M Hsieh; John F Tisdale
Journal:  Exp Hematol       Date:  2015-10-21       Impact factor: 3.084

7.  The chicken hypersensitivity site 4 core insulator blocks promoter interference in lentiviral vectors.

Authors:  Naoya Uchida; Hideki Hanawa; Motoko Yamamoto; Takashi Shimada
Journal:  Hum Gene Ther Methods       Date:  2013-04       Impact factor: 2.396

8.  Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid.

Authors:  Naoya Uchida; Matthew M Hsieh; Kareem N Washington; John F Tisdale
Journal:  Exp Hematol       Date:  2013-05-09       Impact factor: 3.084

9.  Investigating the Barrier Activity of Novel, Human Enhancer-Blocking Chromatin Insulators for Hematopoietic Stem Cell Gene Therapy.

Authors:  Penelope-Georgia Papayanni; Nikoletta Psatha; Panayota Christofi; Xing-Guo Li; Pamela Melo; Monica Volpin; Eugenio Montini; Mingdong Liu; Georgios Kaltsounis; Minas Yiangou; David W Emery; Achilles Anagnostopoulos; Thalia Papayannopoulou; Suming Huang; George Stamatoyannopoulos; Evangelia Yannaki
Journal:  Hum Gene Ther       Date:  2021-10       Impact factor: 4.793

10.  Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2012-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.